1-9 of 9
Anita Zahlten
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Meletios A Dimopoulos, Hang Quach, MDFRACP,FRCPA,MBBS, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD, David S. Siegel, MD PhD, Katja Weisel, MD, Maria Gavriatopoulou, Albert Oriol, MD, Neil K Rabin, Ajay Nooka, MDMPH, Ming Qi, MD PhD, Bifeng Ding, Anita Zahlten-Kumeli, Saad Z. Usmani, MDMBBS,MBA
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-137602
Published: 2020
Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-6.
https://doi.org/10.1182/blood-2019-132629
Published: 2019
Journal Articles

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Clinical Trials & Observations
Thierry Facon, Jae Hoon Lee, Philippe Moreau, Ruben Niesvizky, Meletios Dimopoulos, Roman Hajek, Ludek Pour, Artur Jurczyszyn, Lugui Qiu, Zandra Klippel, Anita Zahlten-Kumeli, Muhtarjan Osman, Bruno Paiva, Jesus San-Miguel
Journal: Blood
Blood (2019) 133 (18): 1953–1963.
https://doi.org/10.1182/blood-2018-09-874396
Published: 2019
Includes: Supplemental data
Journal Articles

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Maria-Victoria Mateos, MD PhD, Jesus G. Berdeja, MD, Meletios A Dimopoulos, MD, David S Siegel, MD PhD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Mei Huang, Martina Sersch, Anita Zahlten-Kumeli, Amy S Kimball, Katja Weisel, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1963.
https://doi.org/10.1182/blood-2018-99-112600
Published: 2018
Journal Articles

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Philippe Moreau, A Keith Stewart, MB, ChB, Antonio Lazzaro, Meletios A Dimopoulos, MD, Michele Cavo, MD, Sikander Ailawadhi, Karim Iskander, Mei Huang, Anita Zahlten-Kumeli, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3244.
https://doi.org/10.1182/blood-2018-99-114863
Published: 2018
Journal Articles

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Meletios A Dimopoulos, MD, Ruben Niesvizky, MD, Philippe Moreau, David S Siegel, MD PhD, Roman Hajek, MD PhD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Mei Huang, Anita Zahlten-Kumeli, Katja Weisel, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3277.
https://doi.org/10.1182/blood-2018-99-118448
Published: 2018
Journal Articles

Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure

Jesus G. Berdeja, MD, Robert M. Rifkin, MD, Roger Lyons, MD, Hui Yang, Anita Zahlten-Kuemeli, Sanjay K. Aggarwal, Karim Iskander, PhD, James Berenson, MD
Journal: Blood
Blood (2016) 128 (22): 2129.
https://doi.org/10.1182/blood.V128.22.2129.2129
Published: 2016
Journal Articles

Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Oliver G. Ottmann, MD, PhD, Daniel J. DeAngelo, MD, PhD, Guillermo Garcia-Manero, Michael Lübbert, Anand Jillella, MD, Mikkael A. Sekeres, MD, MS, Anita Zahlten, PhD, Margaret Squier, MD, PhD, Suddhasatta Acharyya, PhD, Ivo J. Winiger, MD, Pierre Fenaux, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 459.
https://doi.org/10.1182/blood.V118.21.459.459
Published: 2011
Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Richard F. Schlenk, MD, Jürgen Krauter, MD, Markus Schaich, MD, Didier Bouscary, MD, PhD, Hervé Dombret, Ivo J. Winiger, MD, Margaret Squier, MD, PhD, Anita Zahlten, PhD, Lu Wang, PhD, Oliver G. Ottmann, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 423.
https://doi.org/10.1182/blood.V118.21.423.423
Published: 2011